Abstract
The objective was to assess clinical efficacy of 3 dosages of intravenous gammaglobulins to prevent infectious episodes in adult common variable immunodeficiency. We designed a randomized, double blind, dose-assessing study. The setting was at University Hospital, Out-Patient Clinic. Our patients were twenty-one adult patients with common variable immunodeficiency. The measurements were comparative study of the number and severity of infections using 3 various dosages of intravenous gammaglobulins, each given monthly for at least 6 months. Results indicated four hundred and eighty-four infectious episodes occurred while giving 305 infusions of IVIG 200 mg/kg; 205 infectious episodes while giving 170 infusions of 400 mg/kg and 436 infectious episodes while giving 247 infusions of 600 mg/kg. The morbidity scores (infection/infusion) were 1.59, 1.21 and 1.77 respectively (p-N/S). There was no significant difference in the severity of infections on the above 3 dosages, and no difference in the duration of infection-free intervals. The conclusions resulted in no significant differences in morbidity in adult patients with common variable immunodeficiency treated in cross-over pattern with IVIG 200 mg/kg, 400 mg/kg and 600 mg/kg. Thus, high dosages of IVIG are not conferring better protection against infections in such patients.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Consensus on IVIG. 1990. Editorial.Lancet.2:470–472.
Eibl, M., andR. J. Wedgwood. 1989. Intravenous immunoglobulin: a review.Immunodef. Rev. 1(Suppl. 1): 1–42.
Berkman, S. A., M. Lee, andR. G. Gale. 1990. Clinical uses of intravenous immunoglobulin.Ann. Intern. Med. 112:278–292.
Eibl, M. M., andR. J. Wedgwood. 1993. Intravenous immunoglobulin: A review.In Immunodeficiencies. F. S. Rosen and M. Seligmann, editors. Academic Publishers, Harwood, pp. 659–688.
Bernatowska, E., K. Madalinski, W. Janowicz, R. Weremowicz, P. Gutkowski, H. M. Wolf, andM. M. Eibl. 1987. Results of a prospective controlled two-dose crossover study with intravenous immunoglobulin and comparison (retrospective) with plasma treatment.Clin. Immunol. Immunopathol. 43:153–162.
Steele, R. W., R. A. Augustine, A. S. Tannenbaum, andD. J. Marmer. 1985. Intravenous immune globulin for hypogammaglobulinemia: A comparison of opsonizing capacity in recipient sera.Clin. Immunol. Immunopathol. 34:275–283.
Pirofsky, B. 1984. Intravenous immune globulin therapy in hypogammaglobulinemia. AReview. Am. J. Med. 76:53–60.
Cunningham-Rundles, C. 1986. Treatment of AB deficiencies.Vox Sang. (Suppl. 2)51:63–68.
Mankarious, S., M. Lee, S. Fischer, K. H. Pyun, H. D. Ochs, V. A. Oxelius, andR. J. Wedgwood. 1988. The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin.J. Lab. Clin. Med. 112:634–640.
Ochs, H. D., S. H.Fisher, R. J.Wedgwood, D. W.Wara, M. J.Cowan, A. J.Ammann, A.Saxon, M. D.Budinger, R. J.Allred, and R. H.Rousell. 1984. Comparison of highdose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency disease.Am. J. Med. pp. 78–82.
Dwyer, J. M. 1992. Manipulating the immune system with immune globulin.N. Engl. J. Med. 326:107–116.
Gelfand, E. W. 1992. Treatment of autoimmune diseases with intravenous gammaglobulin.Sem. Hemat. (Suppl. 2)29:127–133.
Kaveri, S. V., G. Dietrich, andM. D. Kazatchkine. 1992. Can intravenous immunoglobulin treatment regulate autoimmune responses?Semin. Hematol. (Suppl. 2)29:64–71.
Achiron, A., R. Margalit, R. Hershkoviz, D. Markovits, T. Reshef, E. Melamed, I. R. Cohen, andO. Lider. 1994. Intravenous immunoglobulin treatment of experimental T cellmediated autoimmune disease. Upregulation of T cell proliferation and downregulation of tumor necrosis factorα secretion.J. Clin. Invest. 93:600–605.
Abe, Y., A. Horiuchi, M. Miyake, andS. Kimura. 1994. Anti-cytokine nature of natural human immunoglobulin: One possible mechanism of the clinical effect of intravenous immunoglobulin therapy.Immuno. Rev. 139:5–19.
Sundblad, A., M-A. R. Marcos, E. Malanchere, A. Castro, M. Haury, F. Huetz, A. Nobrega, A. Freitas, andA. Cutinho. 1994. Observations on the mode of action of normal immunoglobulin at high doses.Immunol. Rev. 139:125–158.
Barandun, S., P. Kistler, F. Jeunet, andH. Isliker. 1962. Intravenous administration of human gammaglobulin.Vox Sang. 7:157–174.
Sorensen, R. U., andS. H. Polmar. 1984. Efficacy and safety of high-dose intravenous immune globulin therapy for antibody deficiency syndrome.Am. J. Med. 76:83–90.
Eibl, M. M., L. Cairns, andF. S. Rosen. 1984. Safety and efficacy of a monomeric, functionally intact intravenous IgG preparation in patients with primary immunodeficiency syndromes.Clin. Immunol. Immunopathol. 31:151–160.
World Health Organization Scientific Group Report. 1989. Primary Immunodeficiency Diseases.Immunodeficiency Rev. 1:173–205.
Montanaro, A., andB. Pirofsky. 1984. Prolonged interval high-dose intravenous immunoglobulin in patients with primary immunodeficiency states.Am. J. Med. 76:67–72.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pruzanski, W., Sussman, G., Dorian, W. et al. Relationship of the dose of intravenous gammaglobulin to the prevention of infections in adults with common variable immunodeficiency. Inflammation 20, 353–359 (1996). https://doi.org/10.1007/BF01486738
Issue Date:
DOI: https://doi.org/10.1007/BF01486738